SciSparc Ltd. reports clinical-stage pharmaceutical and intellectual-property developments tied to cannabinoid-based technologies and its majority-owned subsidiary, NeuroThera Labs Inc. The company’s recurring updates cover SCI-110 for Tourette syndrome and Alzheimer’s disease agitation, SCI-210 for autism spectrum disorder and status epilepticus, and combination approaches involving THC, non-psychoactive CBD, PEA and MEAI.
Company news also includes patent activity for CNS, metabolic and antimicrobial-resistance applications; the acquired MUSE™ endoscopic system and related medical-camera intellectual property for GERD procedures; hemp seed oil-based product sales through a controlled subsidiary; and public-company matters such as capital-structure actions, Nasdaq compliance notices, material agreements and financial disclosures.
SciSparc (Nasdaq: SPRC) closed the acquisition of an intellectual property portfolio from Xylo Technologies on January 26, 2026, acquiring patents, trademarks and know‑how centered on the single‑use MUSE™ endoscopic system for transoral fundoplication to treat GERD.
Consideration included ordinary shares representing 19.99% of SciSparc and pre‑funded warrants in lieu of some shares. SciSparc intends to commence immediate commercialization and pursue exclusive regional distributor partnerships in North America, Europe and Latin America. The release notes Xylo previously received $3.0M up front in 2019 under a Greater China licensing deal and cites a MarkNtel market estimate valuing the global GERD device market at $2.5B (2024), projected to $3.03B by 2030 (CAGR 3.24% 2025–2030).
SciSparc (Nasdaq: SPRC) signed a definitive agreement to acquire a portfolio of patents, trademarks and know‑how for endoscopic systems and medical cameras, chiefly the MUSE™ single‑use transoral fundoplication device. The Closing is set for March 8, 2026, at which SciSparc will issue ordinary shares that will represent 19.99% of issued and outstanding share capital to Xylo (or pre‑funded warrants in lieu).
SciSparc plans immediate commercialization after closing, aims to replicate Xylo’s 2019 Greater China licensing model (which generated a $3.0M up‑front payment), and cites a GERD device market roughly $2.5B in 2024, projected to $3.03B by 2030.
SciSparc (Nasdaq: SPRC) received a Nasdaq notification that it is not in compliance with the minimum stockholders’ equity requirement under Rule 5550(b)(1), which requires at least $2,500,000 in equity. The company reported approximately $(81,000) in stockholders’ equity as of June 30, 2025. SciSparc has 45 calendar days (until February 26, 2026) to submit a plan to regain compliance; if accepted Nasdaq may grant up to a 180-day extension to evidence compliance. The notice has no immediate effect on listing and shares will continue trading as SPRC. The company expects to demonstrate compliance as of December 31, 2025 following proceeds from an $4.2 million debenture conversion in August 2025 and its November 2025 registered direct offering.
SciSparc (Nasdaq: SPRC) said NeuroThera Labs received an Israel patent for a proprietary combination of opioids and N-acylethanolamines designed to potentiate analgesia while reducing side effects.
The grant complements existing patents in Europe, Japan, Australia, and Canada. SciSparc holds a controlling interest of approximately 75% in NeuroThera. A pre-clinical study reported that combining palmitoylethanolamide (PEA) with oxycodone prolonged analgesic effect and reduced some oxycodone-related psychoactive adverse events. The release cites a $5.5–$5.7 billion 2024 global oxycodone market estimate and suggests an "opioid-sparing" effect that may lower required opioid doses.
SciSparc (Nasdaq: SPRC) announced on Dec. 2, 2025 that NeuroThera Labs (TSXV: NTLX), in which SciSparc holds a controlling interest of approximately 75%, signed a non-binding term sheet to acquire a majority stake in an Israeli quantum-enabled bio data analytics company.
Under the Term Sheet NeuroThera would acquire 55% equity of the Target Company in exchange for issuing common shares equal to 40% of NeuroThera’s share capital on a non-diluted basis. The Acquisition is subject to due diligence, definitive agreements, corporate and regulatory approvals, and customary closing conditions; there is no assurance the transaction will be completed.
SciSparc (Nasdaq: SPRC) signed a binding term sheet to acquire a treasury of patents, trademarks and IP rights for endoscopic systems and medical cameras from Xylo Technologies, principally the single-use MUSE™ transoral fundoplication system.
The consideration at closing will be ordinary shares representing 19.99% of SciSparc’s issued and outstanding share capital (or, at SciSparc’s option, pre-funded warrants). SciSparc plans to pursue exclusive distributor partnerships to commercialize MUSE across North America, Europe and Latin America. A May 2025 report valued the global GERD device market at $2.5B (2024), projected to $3.03B by 2030 (CAGR 3.24% 2025–2030).
SciSparc (Nasdaq: SPRC) signed a binding term sheet to acquire a treasury of patents, trademarks and know‑how for innovative endoscopic systems and medical cameras, principally the MUSE™ transoral fundoplication system from Xylo Technologies.
Under the term sheet SciSparc will issue upon closing ordinary shares representing 19.99% of issued and outstanding capital (or pre‑funded warrants in lieu). SciSparc plans to pursue exclusive regional distributor partnerships to commercialize MUSE™ across North America, Europe and Latin America. A May 2025 market report values the global GERD device market at $2.5B in 2024, projected to $3.03B by 2030 (CAGR 3.24% 2025–2030).
SciSparc (Nasdaq: SPRC) said on November 20, 2025 that NeuroThera Labs (TSXV: NTLX), in which SciSparc holds approximately 75% controlling interest, filed an Israeli patent application for a combination therapy of MEAI (5-methoxy-2-aminoindane) and N-acylethanolamines such as PEA targeting depression.
The filing expands a joint IP portfolio with Clearmind Medicine (Nasdaq: CMND); the collaboration has produced 13 patents filed to date covering MEAI and N-acylethanolamine combinations for disorders including alcohol use disorder, cocaine addiction, obesity and depression. The release cites preclinical data supporting MEAI's efficacy in reducing addictive behaviors while preserving normal reward pathways.
The announcement references World Health Organization data (August 2025) noting ~332 million people living with depression worldwide (≈5.7% of adults).
SciSparc (Nasdaq: SPRC) closed the acquisition and transfer transaction with Miza III Ventures (now Neurothera Labs Inc., TSXV: NTLX) effective October 22, 2025. SciSparc received 63,300,000 common shares, 4,000,000 warrants exercisable at CAD 0.25 until October 22, 2030, and up to 48,000,000 contingent rights tied to milestones. The Target Assets transferred had an aggregate value of approximately US$11.6 million while Neurothera enterprise value was ~US$3.3 million (including ~US$1.0M cash).
SciSparc holds a controlling stake of ~75%, potentially rising to ~84% if warrants and milestones are fully executed. SciSparc also committed CAD 1.0M via an unsecured convertible note maturing October 22, 2027. Transaction Securities are subject to TSXV escrow and final TSXV acceptance is pending.
SciSparc (Nasdaq: SPRC) announced on October 23, 2025 the closing of the sale of its majority-owned subsidiary MitoCareX to N2OFF (Nasdaq: NITO).
N2OFF purchased 6,622 MitoCareX shares from SciSparc for $700,000, exchanged remaining shares with the sellers for N2OFF common stock equaling 40% of N2OFF’s fully diluted capital, and reconstituted MitoCareX’s board. Sellers are entitled to 30% of N2OFF’s financing proceeds (capped at $1.6M) for five years and may receive up to 25% of N2OFF common stock as milestone-based issuances. MitoCareX focuses on mitochondrial SLC25 targets and uses the MITOLINE™ algorithm plus in vitro screening for anti-cancer small molecules.